Varian, Boston Scientific FDA Approvals Aid Q1 Double-Digit Stock Gains
This article was originally published in The Gray Sheet
Executive Summary
Varian Medical Systems' receipt of 510(k) clearance for its On-Board Imaging tumor tracking accessory helped the radiation oncology firm's stock soar 24.9% in the first quarter - jumping $17.21 to close at $86.31